신생아에서 흡입 일산화질소 치료의 임상적 적응증
Clinical Indications for Inhaled Nitric Oxide Therapy in Neonates
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Nitric oxide (NO) is a colorless, odorless gas that acts as a potent pulmonary vasodilator. When administered via inhalation, NO rapidly diffuses across the alveolarcapillary membrane and binds to hemoglobin, and thus has little effect on the systemic circulation. NO was approved by the United States Food and Drug Administration (US FDA) for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in 1999. Neonatal hypoxic respiratory failure may be caused by persistent pulmonary hypertension of the newborn and other diseases such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome that contribute to pulmonary arterial hypertension. Inhaled NO is the only approved treatment in term and late preterm (>34 weeks) neonates with hypoxic respiratory failure associated with pulmonary hypertension, and it reduces the need for extracorporeal membrane oxygenation. The present article will review the clinical indications for US FDA-approved inhaled NO therapy according to evidence-based clinical studies.
Abstract
Nitric oxide (NO) is a colorless, odorless gas that acts as a potent pulmonary vasodilator. When administered via inhalation, NO rapidly diffuses across the alveolarcapillary membrane and binds to hemoglobin, and thus has little effect on the systemic circulation. NO was approved by the United States Food and Drug Administration (US FDA) for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in 1999. Neonatal hypoxic respiratory failure may be caused by persistent pulmonary hypertension of the newborn and other diseases such as meconium aspiration syndrome, sepsis, birth asphyxia, and respiratory distress syndrome that contribute to pulmonary arterial hypertension. Inhaled NO is the only approved treatment in term and late preterm (>34 weeks) neonates with hypoxic respiratory failure associated with pulmonary hypertension, and it reduces the need for extracorporeal membrane oxygenation. The present article will review the clinical indications for US FDA-approved inhaled NO therapy according to evidence-based clinical studies.
참고문헌 (42)
- DiBlasi RM, "Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure", Respir Care, 55, pp.1717~1745 (2010)
- Gersony WM, "Neonatal pulmonary hypertension: pathophysiology, classification, and etiology", Clinic Peinatol, 11, pp.517~524 (1984)
- Neonatal Inhaled Nitric Oxide Study Group, "Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure", N Engl J Med, 336, pp.597~604 (1997)
- Muraca MC, "Nitric oxide in neonatal hypoxemic respiratory failure", J Matern Fetal Neonatal Med, 25, pp.47~50 (2012)
- Schreiber MD, "Inhaled nitric oxide in premature infants with the respiratory distress syndrome", N Engl J Med, 349, pp.2099~2107 (2003)
- Barrington KJ, "Inhaled nitric oxide for respiratory failure in preterm infants", Cochrane Database Syst Rev, pp.CD000509~ (2006)[DOI]
- Baker CD, "Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia", Pediatr Allergy Immunol Pulmonol, 27, pp.8~16 (2014)
- Konduri GG, "Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn", Pediatr Clin North Am, 56, pp.579~600 (2009)
- Nair J, "Update on PPHN: mechanisms and treatment", Semin Perinatol, 38, pp.78~91 (2014)
- 황종희, "신생아 폐고혈압", 대한주산의학회잡지, 24(1), pp.1~10 (2013), 대한주산의학회
- Barman SA, "RhoA", Rho-kinase signaling: a therapeutic target in pulmonary hypertension, 2009, pp.5, 663~671
- Bin-Nun A, "Role of iNO in the modulation of pulmonary vascular resistance", J Perinatol, 28, pp.S84~92 (2008)
- Finer NN, "Nitric oxide for respiratory failure in infants born at or near term", Cochrane Database Syst Rev, pp.CD000399~ (2006)[DOI]
- Furchgott RF, "The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine", Nature, 288, pp.373~376 (1980)
- Ignarro LJ, "Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide", Proc Natl Acad Sci USA, 84, pp.9265~9269 (1987)
- Palmer RM, "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor", Nature, 327, pp.524~526 (1987)
- Murad F, "The 1996 albert lasker medical research awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate", JAMA, 276, pp.1189~1192 (1996)
- Frostell C, "Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasocontriction", Circulation, 83, pp.2038~2047 (1991)
- Roberts JD, "Inhaled nitric oxide in persistent pulmonary hypertension of the newborn", Lancet, 340, pp.818~819 (1992)
- Kinsella JP, "Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn", Lancet, 340, pp.819~820 (1992)
- Chang YS, "Two cases of nitric oxide inhalation for treatment of severe pulmonary hypertension after surgical repair of congenital diaphragmatic hernia", J Korean Pediatr Soc, 39, pp.1611~1619 (1996)
- Ko SY, "Clinical response to inhaled nitric oxide in persistent pulmonary hypertension of the newborn", J Korean Med Sci, 13, pp.500~506 (1998)
- Stork EK, "Fanaroff and Martin's Neonatal-Perinatal Medicine", pp.1176~1194 (2006), Mosby
- Moore C, "Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase", Thromb Haemost, 104, pp.342~349 (2010)
- 김이경, "흡입 일산화 질소 치료", Neonatal medicine, 15(1), pp.14~21 (2008), 대한신생아학회
- Dhillon R, "The management of neonatal pulmonary hypertension", Arch Dis Child Fetal Neonatal Ed, 97, pp.F223~228 (2012)
- Franco-Belgium Collaborative NO Trial Group, "Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial", Lancet, 354, pp.1066~1071 (1999)
- Roberts JD, Jr, "Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group", N Engl J Med, 336, pp.605~610 (1997)
- Kinsella JP, "Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn", J Pediatr, 131, pp.55~62 (1997)
- Neonatal Inhaled Nitric Oxide Study Group, "Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia", Pediatrics, 99, pp.838~845 (1997)
- Kinsella JP, "Early inhaled nitric oxide therapy in premature newborns with respiratory failure", N Engl J Med, 355, pp.354~364 (2006)
- Mercier JC, "Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial", Lancet, 376, pp.346~354 (2010)
- Konduri GG, "A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure", Pediatrics, 113, pp.559~564 (2004)
- Gonzalez A, "Randomized controlled trial of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension", J Perinatol, 30, pp.420~424 (2010)
- Kinsella JP, "Efficacy of inhalational nitric oxide therapy in the clinical management of persistent pulmonary hypertension of the newborn", Chest, 105, pp.92s~94s (1994)
- Cole FS, "National Institutes of Health consensus development conference statement: inhaled nitric oxide therapy for premature infants", NIH Consens State Sci Statements, 27, pp.1~34 (2010)
- Barrington KJ, "Inhaled nitric oxide for respiratory failure in preterm infants", Cochrane Database Syst Rev, pp.CD000509~ (2010)[DOI]
- Van Meurs KP, "Inhaled nitric oxide for premature infants with severe respiratory failure", N Engl J Med, 353, pp.13~22 (2005)
- Keszler M, "Guideline for rational and cost-effective use of iNO therapy in term and preterm infants", J Clin Neonatol, 1, pp.59~63 (2012)
- Clark RH, "Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group", N Engl J Med, 342, pp.469~474 (2000)
- Luna MS, "Therapeutic strategies in pulmonary hypertension of the newborn: where are we now?", Currt Med Chem, 19, pp.4640~4653 (2012)
- Bizzarro M, "Inhaled nitric oxide for the postoperative management of pulmonary ypertension in infants and children with congenital heart disease", Cochrane Database Syst Rev, pp.CD005055~ (2005)[DOI]